title: Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis.
abstract: BACKGROUND
  Carnitine is an endogenous metabolite and exogenous nutrient with a pivotal role in lipid metabolism. Plasma levels of carnitine are reduced in type 2 Diabetes Mellitus (T2DM). The aim was to evaluate the metabolic effects of the administration of L-carnitine in T2DM.
  
  
  METHODS
  A systematic review was performed. Relevant randomized, controlled-trials trials were searched in Pubmed, Trip Database and Cochrane Library, and selected when they had enough methodological quality assessed with the Jadad scale. Article search strategy included "Carnitine" OR "L-carnitine" AND "Diabetes -Mellitus" OR "Diabetes mellitus, type 2" OR "Noninsulindependent-diabetes mellitus". Meta-analysis was performed, and the difference of means calculated with a 95% confidence interval. Heterogeneity was evaluated with the Q statistic.
  
  
  RESULTS
  The systematic review included 4 trials with 284 patients. Oral L-carnitine lowered fasting plasma glucose [-14.3 mg/dl (CI95% - 23.2 to -5.4); p=0,002], total cholesterol [-7.8 mg/dL (95%CI -15.5 to -0.1); p=0.09], low density lipoprotein [-8.8 mg/dl (CI95% -12.2 to -8.5), p<0.0001], apolipoprotein-B100 [-7.6 mg/dl (CI95% -13.6 to -1.6); p=0.013] and apolipoprotein-A1 [-6.0 mg/dl (CI95% -10.5 a -1.5); p=0.523]. There was no significant heterogeneity. The changes in triglycerides, lipoprotein (a) or HbA(1c) were not significant.
  
  
  CONCLUSIONS
  The administration of L-carnitine in type 2 diabetes mellitus is associated with an improvement in glycaemia and plasma lipids.
authors: Sección de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, León, Spain. avcyo@hotmail.com
authors: A
authors: A
authors: Vidal-Casariego
authors: R
authors: R
authors: Burgos-Peláez
authors: C
authors: C
authors: Martínez-Faedo
authors: F
authors: F
authors: Calvo-Gracia
authors: M Á
authors: MÁ
authors: Valero-Zanuy
authors: L M
authors: LM
authors: Luengo-Pérez
authors: C
authors: C
authors: Cuerda-Compés
mesh_terms: D016632:Apolipoprotein A-I / Q000097:blood; D053299:Apolipoprotein B-100 / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002331:Carnitine / Q000008:administration & dosage / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005215:Fasting; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D016239:MEDLINE; D019518:Postprandial Period; D016032:Randomized Controlled Trials as Topic
chemical_list: D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D008077:Lipoproteins, LDL; D002784:Cholesterol; D002331:Carnitine